(Q44931828)

7 December 2017

title

Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast (English)

1 reference

7 December 2017

0 references

1 reference

fluticasone propionate

1 reference

Lucinda Orsini

1

1 reference

7 December 2017

Sasigaant Limpa-Amara

2

1 reference

7 December 2017

William H Crown

3

1 reference

7 December 2017

Richard H Stanford

4

1 reference

7 December 2017

Khalid Kamal

5

1 reference

7 December 2017

language of work or name

1 reference

1 May 2004

1 reference

Annals of Allergy, Asthma & Immunology

7 December 2017

published in

1 reference

7 December 2017

volume

92

1 reference

7 December 2017

issue

5

1 reference

7 December 2017

page(s)

523-529

1 reference

Potentially avoidable hospitalizations: inequalities in rates between US socioeconomic groups

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961759-0

7 January 2021

The risk of hospitalization in patients with asthma switched from an inhaled corticosteroid to a leukotriene receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961759-0

7 January 2021

One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961759-0

7 January 2021

Low-dose inhaled corticosteroid therapy and risk of emergency department visits for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961759-0

7 January 2021

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961759-0

7 January 2021

Fluticasone propionate versus zafirlukast: effect in patients previously receiving inhaled corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961759-0

7 January 2021

Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961759-0

7 January 2021

Inhaled fluticasone propionate. A pharmacoeconomic review of its use in the management of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961759-0

7 January 2021

The medical treatment of depression, 1991-1996: productive inefficiency, expected outcome variations, and price indexes.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961759-0

7 January 2021

Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961759-0

7 January 2021

The direct cost of care for psoriasis and psoriatic arthritis in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961759-0

7 January 2021

The application of sample selection models to outcomes research: the case of evaluating the effects of antidepressant therapy on resource utilization

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961759-0

7 January 2021

Work disability among adults with asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961759-0

7 January 2021

An economic evaluation of asthma in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961759-0

7 January 2021

10.1016/S1081-1206(10)61759-0

Identifiers

DOI

1 reference

7 December 2017

1 reference